+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mutagenicity studies of (racemic)-4-diethylamino-1,1,-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence



Mutagenicity studies of (racemic)-4-diethylamino-1,1,-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence



Journal of Toxicological Sciences 22(Suppl. 1): 251-261



The mutagenicity of (+-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a new drug for the treatment of urinary frequency and incontinence, was investigated by the reverse mutation test in bacteria, the chromosome aberration test in vitro, and the micronucleus test in mice.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009066266

Download citation: RISBibTeXText


Related references

Mutagenicity studies of RCC-36, the active metabolite of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence. Journal of Toxicological Sciences 22(Suppl. 1): 263-274, 1997

Mutagenicity studies of -4-diethylamino-1,1,-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate , a novel drug for urinary frequency and incontinence. Journal of Toxicological Sciences 22(Suppl. 1): 251-261, 1997

Mutagenicity studies of (+/-)-4-diethylamino-1,1,-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence. Journal of Toxicological Sciences 22(Suppl. 1): 251-261, 1997

Mutagenicity studies of RCC-36, the active metabolite of -4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate , a novel drug for urinary frequency and incontinence. Journal of Toxicological Sciences 22(Suppl. 1): 263-274, 1997

Mutagenicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence. Journal of Toxicological Sciences 22(Suppl. 1): 263-274, 1997

Antigenicity study of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence. Journal of Toxicological Sciences 22(Suppl. 1): 307-313, 1997

Single-dose toxicity studies of (racemic)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice, rats and dogs. Journal of Toxicological Sciences 22(Suppl. 1): 1-13, 1997

Two-year dietary carcinogenicity study of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl-2 cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats. Journal of Toxicological Sciences 22(Suppl. 1): 289-306, 1997

Reproductive and developmental toxicity studies of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence: Teratogenicity study in rabbits by oral administration. Journal of Toxicological Sciences 22(Suppl. 1): 229-237, 1997

Reproductive and developmental toxicity studies of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence: Teratogenicity study in rats by oral administration. Journal of Toxicological Sciences 22(Suppl. 1): 213-228, 1997

Seventy-eight-week dietary carcinogenicity study of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice. Journal of Toxicological Sciences 22(Suppl. 1): 275-287, 1997

Toxicokinetics of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice and rats during 13-week dietary administration. Journal of Toxicological Sciences 22(Suppl. 1): 177-185, 1997

The mechanism of increased thyroidal function caused by (racemic)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, administration in rats. Journal of Toxicological Sciences 22(Suppl. 1): 187-199, 1997

Intraperitoneal single-dose toxicity studies of active metabolite, optical isomers, hydrolysis products and bi-product of (racemic)-4-diethylamino-1, 1-dimethylbut-2-yn-1-yl-2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in mice. Journal of Toxicological Sciences 22(Suppl. 1): 15-25, 1997

Oral single-dose and 13-week repeat-dose toxicity studies of RCC-36, the active metabolite of (racemic)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl-2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence, in rats. Journal of Toxicological Sciences 22(Suppl. 1): 93-124, 1997